VJOncology is committed to improving our service to you

ESMO 2018 | Where is ovarian cancer treatment headed?

VJOncology is committed to improving our service to you

Domenica Lorusso

The landscape of ovarian cancer treatment is rapidly changing, with PARP inhibitors moving into the first-line setting and new research addressing homologous recombination deficiency-positive patients. Concurrently, translational medicine seeks to optimize treatment strategies by comparing combination therapies and immunotherapies, says Domenica Lorusso, MD, PhD, of the IRCCS National Cancer Institute, Milan, Italy. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter